TMO

ACCE-researched
Thermo Fisher Scientific Inc Common Stock
Healthcare · Diagnostics & Research · NYSE · United States
$651.45-1.04%
Market cap $240.9BNext earnings 2026-10-28Updated Sep 19, 2026
FAIR VALUE · CONSENSUS
$651.45+0.0%
confidence-weighted across 4 of 6 models
Now $651.45
$651.45
$201.05$670.90
TrimSilver67
Price vs fair value
38.7% above
-27.9% to fair value
ACCE score
68
out of 100
Analysts
81% buy
31 covering
P/E
35.1x
forward 23.7x
1-year return
+35.4%
Dividend yield
0.27%
Unlock the ACCE read
INVESTOR

Overview

Reports in 37 days, last quarter beat by 0.1%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+37.2% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bullish81% buy · 31 covering analysts
● Strong buy 18● Buy 7● Hold 6● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 50% of peers
low 0.0x35.1xhigh 106.5x
ROEbetter than 67% of peers
low -13%14%high 23%
Div yieldbetter than 50% of peers
low 0.0%0.3%high 0.9%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
DHRDanaher Corporation Common Stock$148.9B37.87.6%0.350.7%-Compare
NTRANatera Inc. Common Stock$53.2B--12.5%0.050.0%-Compare
LONN.SWLonza Group$46.2B35.212.9%0.460.9%-Compare
AAgilent Technologies Inc. Common Stock$44.1B30.921.0%0.500.7%-Compare
IQVIQVIA Holdings Inc. Common Stock$43.9B33.122.8%2.420.0%-Compare
WATWaters Corporation Common Stock$41.4B106.51.9%0.730.0%-Compare

Sector report card

Where TMO ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 37 days, last quarter beat by 0.1%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+6.8%
1 month
+6.2%
3 months
+40.2%
6 months
+37.3%
YTD
+12.4%
1 year
+35.4%

SEC filings

40 filings
September 2026
Sep 1
Form 4Insider transactionPeriod 2026-08-28
Sep 1
Form 4Insider transactionPeriod 2026-08-28
Sep 1
Form 4Insider transactionPeriod 2026-08-28
37 more filings + AI summaries on Investor+.INVESTOR